

Axio BioPharma and The Bioforge Partner to Unlock Historical Biomanufacturing Data for AI-Driven Process Optimization

Partnership pairs Axio Lattice with BioOptima AI™ to unlock historical process knowledge while preserving data ownership

MADISON, WI, UNITED STATES, August 10, 2026 /EINPresswire.com/ -- [Axio BioPharma](#), a vendor-neutral data infrastructure company for biomanufacturing, today announced a strategic partnership with [The Bioforge](#), developer of the BioOptima

AI™ platform, to help biopharmaceutical companies unlock historical process data and use it to inform future development and manufacturing decisions.



Through the collaboration, the companies will work to establish interoperability between Axio Lattice and BioOptima AI™. The planned connection is intended to help customers make process data comparable across sites, systems, and organizations while allowing the underlying data to remain within its original environment and under the control of its existing owner.

BioOptima AI™ tells scientists which experiment to run next by continuously learning from experimental and process data. The platform delivers value from the first experiment, even for customers with little or no historical data, and continuously improves as every new experimental results are generated.

Axio Lattice is a vendor-neutral coordination and translation layer for biomanufacturing data. For companies with years of process information distributed across systems such as laboratory information management systems, manufacturing execution systems, electronic laboratory notebooks, historians, enterprise resource planning platforms, and quality management systems, Lattice is designed to make that information comparable without requiring it to be copied into a centralized repository.

Together, the platforms are intended to give biomanufacturers a pathway to begin AI-supported

process optimization using both newly generated information and existing process knowledge that may otherwise remain fragmented across sites and systems.

“BioOptima AI™ can deliver value from the first experiment, whether a customer has an extensive historical data set or is starting from scratch,” said Dharini Govindarajan, Co-Founder and Chief Operating Officer of The Bioforge. “For organizations with years of process knowledge distributed across different systems, Axio Lattice creates a richer, connected foundation from which BioOptima AI™ can learn, while allowing the underlying data to remain where it is. This collaboration is about helping customers use more of the knowledge they already have while continuing to improve with every new experiment.”

Many biopharmaceutical organizations have accumulated significant amounts of development and manufacturing data, but differences in formats, terminology, systems, and site-level practices can make that information difficult to compare or reuse. The problem compounds when a program spans two companies. A sponsor and its manufacturing partner each hold part of the process record, and neither will put raw process data into a system the other operates. Consolidating into a single repository is not an option either side will accept. Moving all of that data into a new centralized system can also create operational, security, ownership, and information technology challenges.

The planned Axio Lattice and BioOptima AI™ workflow is intended to address that gap. Lattice would coordinate and translate process information so it can be compared across environments, while BioOptima AI™ would use the resulting context to guide experimental decisions. The data would remain where it is currently stored, without changing ownership.

“Biomanufacturers should not have to choose between leaving valuable historical knowledge stranded and taking on a large, disruptive data-centralization project,” said Justin Byers, Founder and Chief Executive Officer of Axio BioPharma. “Our goal with Lattice is to make process data comparable across sites, systems, and organizations without moving it or changing who owns it. BioOptima AI™ can then learn from a much broader foundation of process knowledge while the underlying data stays where it belongs.”

As part of the partnership, Axio BioPharma and The Bioforge plan to explore coordinated workflows, proof-of-concept pilots, joint customer opportunities, and co-branded technical and educational content. The companies may also collaborate on case studies, application notes, performance benchmarks, and presentations demonstrating how connected historical data can support more informed bioprocess development.

By combining The Bioforge’s Adaptive AI capabilities with Axio BioPharma’s approach to coordinating data across organization boundaries, the companies aim to help development teams move beyond isolated data sets and make better use of institutional process knowledge without creating another large information technology project.

About Axio BioPharma

Axio BioPharma is a vendor-neutral data infrastructure company for biomanufacturing. Axio Lattice is a coordination and translation layer that lets pharma sponsors and their manufacturing partners work from the same process data across organizational boundaries, without moving data or changing ownership. Axio Forge is a high-throughput non-GMP antibody lab producing research-grade monoclonal antibodies on a 3-5 week turnaround. Axio is headquartered in Madison, Wisconsin.

To learn more, visit www.axiobiopharma.com and follow us on LinkedIn (<https://www.linkedin.com/company/axio-biopharma/>).

About The Bioforge

The Bioforge develops BioOptima AI™, an adaptive AI platform that tells scientists which experiment to run next. By continuously learning from experimental and process data, BioOptima AI™ helps bioprocess teams optimize strain engineering, process development and scale-up with fewer experiments and faster development timelines. Whether customers are starting with limited historical information or decades of existing process knowledge, BioOptima AI™ delivers value from the first experiment and becomes smarter with every result.

Learn more at www.thebioforge.com and LinkedIn (<https://www.linkedin.com/company/the-bioforge/>).

Media Contact

Madelyn De Los Santos
Putnam Insights
madelyn@putnaminsights.com

This press release can be viewed online at: <https://www.einpresswire.com/article/932267166>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.